Fibrosis is a strong predictor of advancing NASH, and IL-6 concentration in serum and in liver tissue correlates with inflammation and fibrosis; meanwhile, ACC and FAS expression in NASH patients correlated inversely with the fibrosis stage [69]. The gene discussed is FAS; the disease is metabolic dysfunction-associated steatohepatitis.